Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30509494 | 1.00 | DGAT1 (0.36) | DGAT1NPC1MAPTCDC7PIM1 | |
| SCHEMBL4817809 | 0.83 | NPC1 (0.37) | DGAT1NPC1MAPTCDC7PIM1 | |
| SCHEMBL29959046 | 0.83 | NPC1 (0.37) | DGAT1NPC1MAPTCDC7PIM1 | |
| SCHEMBL1963517 | 0.82 | NPC1 (0.36) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL20765139 | 0.82 | DGAT1 (0.40) | DGAT1NPC1MAPTCDC7PIM1 | |
| SCHEMBL30381397 | 0.82 | DGAT1 (0.40) | DGAT1NPC1MAPTCDC7PIM1 | |
| SCHEMBL20765159 | 0.81 | DGAT1 (0.42) | DGAT1NPC1MAPTCDC7PIM1 | |
| SCHEMBL30380591 | 0.81 | DGAT1 (0.42) | DGAT1NPC1MAPTCDC7PIM1 | |
| SCHEMBL31554406 | 0.80 | NPC1 (0.35) | NPC1MAPTCDC7PIM1CDK9 | |
| SCHEMBL15586644 | 0.80 | NPC1 (0.38) | NPC1MAPTCDC7PIM1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| EP-4214199-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK2A1 | DGAT1 3673/4885NPC1 1692/4885MAPT 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.